These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31718953)

  • 1. Increased platelet inhibition after switching from prasugrel to low-dose ticagrelor in Japanese patients with prior myocardial infarction.
    Tateishi K; Saito Y; Kitahara H; Nakayama T; Fujimoto Y; Kobayashi Y
    J Cardiol; 2020 May; 75(5):473-477. PubMed ID: 31718953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction.
    Kerneis M; Silvain J; Abtan J; Hauguel M; Barthélémy O; Payot L; Brugier D; Galier S; Collet JP; Montalescot G
    Arch Cardiovasc Dis; 2015 Oct; 108(10):502-10. PubMed ID: 26113480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
    Franchi F; Faz GT; Rollini F; Park Y; Cho JR; Thano E; Hu J; Kureti M; Aggarwal N; Durairaj A; Been L; Zenni MM; Guzman LA; Suryadevara S; Antoun P; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2016 Jun; 9(11):1089-98. PubMed ID: 27013060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pharmacodynamic study of the optimal P2Y12 inhibitor regimen for East Asian patients with acute coronary syndrome.
    Lee JH; Ahn SG; Park B; Park SW; Kang YS; Lee JW; Youn YJ; Ahn MS; Kim JY; Yoo BS; Lee SH; Yoon J
    Korean J Intern Med; 2015 Sep; 30(5):620-8. PubMed ID: 26354056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switch to Ticagrelor in critical limb ischemia antiplatelet study (STT-CLIPS).
    Clavijo LC; Dhillon A; Al-Asady N; Matthews RV; Caro J; Tun H; Rowe V; Shavelle DM
    Cardiovasc Revasc Med; 2018; 19(3 Pt B):319-323. PubMed ID: 29329963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
    Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
    Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in Japanese patients with stable coronary artery disease.
    Nishi T; Ariyoshi N; Nakayama T; Fujimoto Y; Sugimoto K; Takahara M; Wakabayashi S; Koshizaka M; Hanaoka H; Kobayashi Y
    Circ J; 2015; 79(11):2439-44. PubMed ID: 26310876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P2Y
    Guimarães LF; Généreux P; Silveira D; Pesaro AE; Falcão F; Barbosa BR; de Souza CF; Fonseca FA; Alves CM; Carvalho AC; Stone GW; Caixeta A
    Int J Cardiol; 2017 Mar; 230():204-208. PubMed ID: 28062136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching acute coronary syndrome patients from prasugrel to clopidogrel.
    Kerneis M; Silvain J; Abtan J; Cayla G; O'Connor SA; Barthélémy O; Vignalou JB; Beygui F; Brugier D; Martin R; Collet JP; Montalescot G
    JACC Cardiovasc Interv; 2013 Feb; 6(2):158-65. PubMed ID: 23428007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High residual platelet reactivity after switching from clopidogrel to low-dose prasugrel in Japanese patients with end-stage renal disease on hemodialysis.
    Ohno Y; Kitahara H; Fujii K; Kohno Y; Ariyoshi N; Nishi T; Fujimoto Y; Kobayashi Y
    J Cardiol; 2019 Jan; 73(1):51-57. PubMed ID: 30055865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction.
    Lee YS; Jin CD; Kim MH; Guo LZ; Cho YR; Park K; Park JS; Park TH; Kim YD
    Circ J; 2015; 79(6):1248-54. PubMed ID: 25959558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensified P2Y12 inhibition for high-on treatment platelet reactivity.
    Mshelbwala FS; Hugenberg DW; Kreutz RP
    J Thromb Thrombolysis; 2020 Oct; 50(3):619-627. PubMed ID: 32152791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin withdrawal in patients treated with ticagrelor presenting with non-ST elevation myocardial infarction.
    Beigel R; Mazin I; Koifman E; Shechter M; Pres H; Shlomo N; Rosenberg N; Asher E; Matetzky S
    J Thromb Haemost; 2018 Apr; 16(4):663-669. PubMed ID: 29443445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Third-Generation P2Y12 Inhibitors in East Asian Acute Myocardial Infarction Patients: A Nationwide Prospective Multicentre Study.
    Kang J; Han JK; Ahn Y; Chae SC; Kim YJ; Chae IH; Hur SH; Seong IW; Chae JK; Cho MC; Seung KB; Jeong MH; Yang HM; Park KW; Kang HJ; Koo BK; Kim HS;
    Thromb Haemost; 2018 Mar; 118(3):591-600. PubMed ID: 29534250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia.
    Jakubowski JA; Hoppe CC; Zhou C; Smith BE; Brown PB; Heath LE; Inusa B; Rees DC; Small DS; Gupta N; Yao S; Heeney M; Kanter J
    Thromb Haemost; 2017 Feb; 117(3):580-588. PubMed ID: 27929203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y
    Franchi F; Rollini F; Faz G; Rivas JR; Rivas A; Agarwal M; Briceno M; Wali M; Nawaz A; Silva G; Shaikh Z; Maaliki N; Fahmi K; Been L; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Baber U; Mehran R; Jennings LK; Bass TA; Angiolillo DJ
    J Am Heart Assoc; 2020 Apr; 9(8):e015865. PubMed ID: 32306797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effects of P2Y12 receptor antagonists on platelet function and clinical outcomes in patients undergoing Primary PCI: A substudy of the HEAT-PPCI trial.
    Shahzad A; Khanna V; Kemp I; Shaw M; Mars C; Cooper R; Wilson K; Curzen N; Stables RH
    EuroIntervention; 2018 Mar; 13(16):1931-1938. PubMed ID: 29336311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized Comparison of Oral P2Y
    Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
    JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prasugrel or Ticagrelor in ST-Segment-Elevation Myocardial Infarction Patients With Diabetes Mellitus.
    Sardella G; Mancone M; Stio RE; Cavallo E; Di Roma A; Colantonio R; Calcagno S
    Circulation; 2017 Aug; 136(6):602-604. PubMed ID: 28784829
    [No Abstract]   [Full Text] [Related]  

  • 20. A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study.
    Jin C; Kim MH; Bang J; Serebruany V
    Cardiology; 2017; 138(4):201-206. PubMed ID: 28810251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.